This review describes the common effects of psychotropic drugs on the cardiovascular
system and offers guidance for practical management. Selected reports from the literature …

Patients affected by psychotic disorders are more likely to develop high rates of co-
morbidities, such as obesity, type 2 diabetes, dyslipidemias, hypertension, metabolic …

Objective: The purpose of this study was to assess the efficacy of metformin in preventing
olanzapine-induced weight gain. Method: Forty patients with schizophrenia were randomly …

Objectives: The presence of metabolic abnormalities is an important risk factor for
cardiovascular disease and diabetes. There are limited data on the prevalence of the …

Metabolic syndrome (MetS), a constellation of central obesity, hypertension, dyslipidaemia
and glucose intolerance, is highly prevalent in individuals with schizophrenia and conveys …

Objectives: Metabolic side effects of antipsychotic treatment include weight gain,
dyslipidemia and increased susceptibility to diabetes. Patients with schizophrenia have …

OBJECTIVE Several second-generation antipsychotic (SGA) drugs have been associated
with weight gain, hyperglycemia, and dyslipidemia. We evaluated whether glucose and lipid …

People with schizophrenia commonly lack insight, that is, they are unaware of their illness
and the consequences thereof. One of the most important consequences of lack of insight is …

Beside the therapeutic improvement over first-generation antipsychotics, the fact that
prescription of atypical agents is also associated to the emergence of severe metabolic …

Background Antipsychotic-associated side effects are well known and represent a significant
treatment challenge. Still, few large studies have investigated the overall side effect burden …